Abstract

IntroductionHuman papillomavirus (HPV) is the most common sexually transmitted infection (STI) worldwide. Despite recommendations for HPV vaccination of young women from health authorities, parental concerns were raised whether vaccination could induce unsafe sexual behaviour in young women. Therefore, the primary aim of this study was to investigate if HPV vaccination in healthcare seeking adult women in Luxembourg was associated with unsafe sexual behaviour.MethodsSeven hundred twenty-nine women (mean age = 22.5; range 18–43 years) were recruited either at Luxembourg family planning centres or at private gynaecology practices. All participants completed a questionnaire on vaccination status and sexual behaviour. Poisson and logistic regressions were used to study the association between sexual behaviour and vaccination status (N = 538). Both models were restricted to women younger than 26 years, since the first cohort being vaccinated would be 25 years old at the time of sampling. Assortativity of sexual mixing by age was also assessed for further transmission modelling for women <30 years reporting age of last/current sexual partner (N = 649). Women older than 29 years were excluded from the assortativity analysis due to restricted sample size.ResultsIn total, 386/538 (71.8%) of participants reported receiving HPV vaccine. Vaccination uptake significantly varied by nationality and was higher in Portuguese 112/142 (78.9%) and in Luxembourgish 224/313(71.6%) residents, and lower in residents of other nationalities 50/83 (60.2%) (p = 0.011). HPV vaccination was not associated with unsafe sexual behaviour such as shorter relationship duration with current or last sexual partner (odds ratio (OR) = 1.05, 95% CI [0.94–1.16]), younger age of sexual debut (OR = 1.00, 95% CI [0.88–1.14]), increased number of lifetime sexual partners (OR = 0.95, 95% CI [0.87–1.03), higher age difference with sexual partner (OR = 1.01, 95% CI [0.95–1.08]), condom use (OR = 0.97, 95% CI [0.60–1.56]), nor with other factors like smoking (OR = 0.73, 95% CI [0.47–1.15]) and nationality. HPV vaccination was only associated with younger age (OR = 0.84, 95% CI [0.75–0.94]). Relationship duration, age of sexual debut, age difference with sexual partner, smoking, age and non-Portuguese foreign nationality were predictors of number of lifetime sexual partners. Assortativity analysis revealed that young women chose sexual partners who were 2.3 years older on average.ConclusionsOur study found no association between unsafe sexual behaviour and HPV vaccination.

Highlights

  • Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) worldwide

  • Socio demographic data collected via this questionnaire included: age, nationality, age of current sexual partner or last sexual partner, number of lifetime sexual partners, condom use, age at first intercourse, smoking, self-reported vaccination status, vaccine type and date

  • We studied the association between vaccination status and sexual behaviour using simple and multivariable logistic regression

Read more

Summary

Introduction

Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) worldwide. Poisson and logistic regressions were used to study the association between sexual behaviour and vaccination status (N = 538) Both models were restricted to women younger than 26 years, since the first cohort being vaccinated would be 25 years old at the time of sampling. HPV vaccination was not associated with unsafe sexual behaviour such as shorter relationship duration with current or last sexual partner (odds ratio (OR) = 1.05, 95% CI [0.94–1.16]), younger age of sexual debut (OR = 1.00, 95% CI [0.88–1.14]), increased number of lifetime sexual partners (OR = 0.95, 95% CI [0.87–1.03), higher age difference with sexual partner (OR = 1.01, 95% CI [0.95–1.08]), condom use (OR = 0.97, 95% CI [0.60–1.56]), nor with other factors like smoking (OR = 0.73, 95% CI [0.47–1.15]) and nationality. In 2018, following an update of WHO recommendations, the policy changed again offering the nonavalent vaccine for 9–13 year old girls and boys (Superior Council of Infectious Diseases, 2019)

Objectives
Methods
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call